Having trouble accessing articles? Reset your cache.

Arzerra ofatumumab: Interim Phase II data

Interim data from a single-arm, open-label, international Phase II trial in 81 patients who are ineligible for or relapsed following

Read the full 208 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE